Condensed Ring Compounds for H-PGDS Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compounds do not effectively inhibit hematopoietic prostaglandin D synthase (H-PGDS), which is involved in various diseases such as allergic, inflammatory, and neuromuscular disorders.
Innovation Solution
Development of a novel condensed ring compound represented by Formula (I) with specific substituents that exhibit excellent H-PGDS inhibitory activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing pharmaceutical compounds are used, then structural diversity is limited, but H-PGDS inhibitory activity is insufficient
Solution Approach 1:
The compound is divided into three main structural segments: a heteroaryl group (ring Y), a linker L1, and a substituted cyclohexyl or bicyclo[2.2.2]octan-1-yl group. This segmentation allows independent optimization of each segment for H-PGDS binding affinity and pharmacokinetic properties, resolving the contradiction between structural diversity and inhibitory activity.
Solution Approach 2:
The invention creates composite molecular structures by combining heteroaryl rings with specific substituent patterns (R1-R8) and rigid cyclohexyl or bicyclo[2.2.2]octanyl frameworks. This composite approach generates diverse structures with optimized H-PGDS inhibition, overcoming the limitations of existing single-structure compounds.
2Reliability
If compound structure is simplified, then ease of synthesis is improved, but H-PGDS inhibitory activity decreases
Solution Approach 1:
The invention introduces specific substituent patterns (R1-R8) at localized positions on the cyclohexyl or bicyclo[2.2.2]octanyl ring system. These local modifications optimize H-PGDS binding without requiring complex overall molecular architecture, balancing synthesizability with inhibitory activity.
Solution Approach 2:
The invention optimizes specific molecular parameters including the heteroaryl ring type (ring Y), linker length and composition (L1), and substituent positions (R1-R8). By systematically varying these parameters, the invention achieves high H-PGDS inhibition with structures that remain synthetically accessible.
3Reliability
If specific substituent patterns are introduced, then H-PGDS inhibitory activity is enhanced, but molecular complexity increases
Solution Approach 1:
The invention extracts and optimizes the essential pharmacophoric elements: a heteroaryl group connected via a linker to a substituted cyclohexyl or bicyclo[2.2.2]octan-1-yl group. By focusing on these extracted key elements rather than exploring all possible molecular complexities, the invention achieves high H-PGDS inhibition with controlled molecular complexity.
Data Source
AI summary
The present invention provides a compound having a hematopoietic prostaglandin D synthase (H-PGDS) inhibitory activity and being useful for preventing or treating a disease involving the enzyme, and a pharmaceutical composition comprising the compound. Specifically, the present invention provides a compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom and the like, R3 represents a hydrogen atom and the like, R4 represents a hydrogen atom and the like, R5 represents a hydrogen atom and the like, W represents an oxygen atom and the like, and X represents a C1-6 alkyl group and the like.]